Narkolepsie

Die Narkolepsie ist eine seltene neurologische Schlaferkrankung, die vor allem Jugendliche und junge Erwachsene betrifft. Hauptsymptome sind die Tagesschläfrigkeit mit Schlafattacken und Kataplexien. Da die Tagesschläfrigkeit ein Symptom vieler Erkrankungen ist und die Narkolepsie für die meisten Neurologen, die nicht schlafmedizinisch tätig sind, eine „exotische“ Erkrankung ist, stellt sie oft eine diagnostische Herausforderung dar.

• Literatur

• 1 Ohayon MM, Priest RG, Zulley J. et al. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 2002; 58: 1826-1833
• 2 Dauvilliers Y, Montplaisir J, Molinari N. et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001; 57: 2029-2033
• 3 Peyron C, Faraco J, Rogers W. et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991-997
• 4 Sakurai T, Amemiya A, Ishii M. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 573-585
• 5 Peyron C, Tighe DK, van den Pol AN. et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998; 18: 9996-10015
• 6 Vaudano AE, Pizza F, Talami F. et al. The neuronal network of laughing in young patients with untreated narcolepsy. Neurology 2019; 92: e504-e515
• 7 Tabuchi S, Tsunematsu T, Black SW. et al. Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function. J Neurosci 2014; 34: 6495-6509
• 8 Shan L, Balesar R, Swaab DF. et al. Reduced Numbers of Corticotropin-Releasing Hormone Neurons in Narcolepsy Type 1. Ann Neurol 2022; 91: 282-288
• 9 Valko PO, Gavrilov YV, Yamamoto M. et al. Increase of histaminergic tuberomammillary neurons in narcolepsy. Ann Neurol 2013; 74: 794-804
• 10 Melzi S, Morel AL, Scoté-Blachon C. et al. Histamine in murine narcolepsy: What do genetic and immune models tell us?. Brain Pathol 2022; 32: e13027
• 11 Barateau L, Pizza F, Plazzi G. et al. Narcolepsy. J Sleep Res 2022; 31: e13631
• 12 Latorre D, Kallweit U, Armentani E. et al. T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature 2018; 562: 63-68
• 13 Partinen M, Kornum BR, Plazzi G. et al. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol 2014; 13: 600-613
• 14 Tesoriero C, Codita A, Zhang MD. et al. H1N1 influenza virus induces narcolepsy-like sleep disruption and targets sleep-wake regulatory neurons in mice. Proc Natl Acad Sci U S A 2016; 113: E368-E377
• 15 Thannickal TC, Moore RY, Nienhuis R. et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469-474
• 16 Dauvilliers Y, Baumann CR, Carlander B. et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 2003; 74: 1667-1673
• 17 Thannickal TC, Nienhuis R, Siegel JM. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep 2009; 32: 993-998
• 18 Stuck BA, Maurer JT, Schlarb AA. et al. Praxis der Schlafmedizin: Diagnostik, Differenzialdiagnostik und Therapie bei Erwachsenen und Kindern. Berlin: Springer; 2017
• 19 Dauvilliers Y, Billiard M, Montplaisir J. Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol 2003; 114: 2000-2017
• 20 Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007; 369: 499-511
• 21 Pizza F, Jaussent I, Lopez R. et al. Car Crashes and Central Disorders of Hypersomnolence: A French Study. PLoS One 2015; 10: e0129386
• 22 Baumann CR, Mignot E, Lammers GJ. et al. Challenges in diagnosing narcolepsy without cataplexy: a consensus statement. Sleep 2014; 37: 1035-1042
• 23 Pillen S, Pizza F, Dhondt K. et al. Cataplexy and Its Mimics: Clinical Recognition and Management. Curr Treat Options Neurol 2017; 19: 23
• 24 Bassetti CLA, Kallweit U, Vignatelli L. et al. European guideline and expert statements on the management of narcolepsy in adults and children. J Sleep Res 2021; 30: e13387
• 25 Plazzi G, Serra L, Ferri R. Nocturnal aspects of narcolepsy with cataplexy. Sleep Med Rev 2008; 12: 109-128
• 26 Dauvilliers Y, Jennum P, Plazzi G. Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia in narcolepsy. Sleep Med 2013; 14: 775-781
• 27 Kok SW, Overeem S, Visscher TL. et al. Hypocretin deficiency in narcoleptic humans is associated with abdominal obesity. Obes Res 2003; 11: 1147-1154
• 28 Sansa G, Iranzo A, Santamaria J. Obstructive sleep apnea in narcolepsy. Sleep Med 2010; 11: 93-95
• 29 Jennum PJ, Plazzi G, Silvani A. et al. Cardiovascular disorders in narcolepsy: Review of associations and determinants. Sleep Med Rev 2021; 58: 101440
• 30 Barateau L, Lopez R, Chenini S. et al. Depression and suicidal thoughts in untreated and treated narcolepsy: Systematic analysis. Neurology 2020; 95: e2755-e27e68
• 31 Plazzi G, Pizza F, Palaia V. et al. Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain 2011; 134: 3477-3489
• 32 Andlauer O, Moore Ht, Hong SC. et al. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep 2012; 35: 1247-1255F
• 33 Thorpy MJ, Krieger AC. Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med 2014; 15: 502-507
• 34 American Academy of Sleep Medicine. ICSD-3: International Classification of Sleep Disorders 3rd ed. (2014).. Zugriff am 16. Juni 2025 unter: https://aasm.org/wp-content/uploads/2019/05/ICSD3-TOC.pdf
• 35 Pizza F, Barateau L, Jaussent I. et al. Validation of Multiple Sleep Latency Test for the diagnosis of pediatric narcolepsy type 1. Neurology 2019; 93: e1034-e1044
• 36 Ægidius HM, Kruse L, Christensen GL. et al. Pre-treatment of blood samples reveal normal blood hypocretin/orexin signal in narcolepsy type 1. Brain Commun 2021; 3: fcab050
• 37 Lopez R, Doukkali A, Barateau L. et al. Test-Retest Reliability of the Multiple Sleep Latency Test in Central Disorders of Hypersomnolence. Sleep 2017; 40
• 38 Goldbart A, Peppard P, Finn L. et al. Narcolepsy and predictors of positive MSLTs in the Wisconsin Sleep Cohort. Sleep 2014; 37: 1043-1051
• 39 Lammers GJ, Bassetti CLA, Dolenc-Groselj L. et al. Diagnosis of central disorders of hypersomnolence: A reappraisal by European experts. Sleep Med Rev 2020; 52: 101306
• 40 Barateau L, Dauvilliers Y. Recent advances in treatment for narcolepsy. Ther Adv Neurol Disord 2019; 12: 1756286419875622.
• 41 Szakacs Z, Dauvilliers Y, Mikhaylov V. et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017; 16: 200-207
• 42 Thorpy MJ. Recently Approved and Upcoming Treatments for Narcolepsy. CNS Drugs 2020; 34: 9-27
• 43 Krahn LE, Arand DL, Avidan AY. et al. Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine. J Clin Sleep Med 2021; 17: 2489-2498
• 44 Dauvilliers Y, Plazzi G, Mignot E. et al. Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1. N Engl J Med 2025; 392: 1905-1916
• 45 Giannoccaro MP, Sallemi G, Liguori R. et al. Immunotherapy in Narcolepsy. Curr Treat Options Neurol 2020; 22: 2